MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

Search

Pacific Biosciences of California Inc

Închisă

SectorSănătate

1.38 -6.76

Rezumat

Modificarea prețului

24h

Curent

Minim

1.36

Maxim

1.49

Indicatori cheie

By Trading Economics

Venit

-428M

-426M

Vânzări

-2.1M

37M

Marjă de profit

-1,146.812

Angajați

575

EBITDA

-420M

-403M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+46.31% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

99M

438M

Deschiderea anterioară

8.14

Închiderea anterioară

1.38

Sentimentul știrilor

By Acuity

64%

36%

335 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Pacific Biosciences of California Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iul. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 iul. 2025, 21:14 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 iul. 2025, 21:04 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 iul. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 iul. 2025, 22:47 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:30 UTC

Market Talk
Câștiguri

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 iul. 2025, 22:04 UTC

Market Talk
Câștiguri

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 iul. 2025, 22:03 UTC

Achiziții, Fuziuni, Preluări

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 iul. 2025, 21:58 UTC

Market Talk
Câștiguri

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 iul. 2025, 21:57 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:47 UTC

Câștiguri

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 iul. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 iul. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 iul. 2025, 21:38 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 iul. 2025, 21:22 UTC

Achiziții, Fuziuni, Preluări

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 21:05 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:04 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 iul. 2025, 21:02 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 20:59 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

17 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Pacific Biosciences of California Inc Așteptări

Obiectiv de preț

By TipRanks

46.31% sus

Prognoză pe 12 luni

Medie 2.18 USD  46.31%

Maxim 3 USD

Minim 1.25 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPacific Biosciences of California Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

7 ratings

4

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.13 / N/ASuport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

335 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.